Graft vs. host disease (GVHD) remains one of the main problems associated with bone marrow transplantation. The current studies were undertaken to determine whether treatment of the donor inoculum with the anticytotoxic cell compound L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) would alter the development of GVHD in a murine model.
Introduction
Graft vs. host disease (GVHD)' remains one of the major problems preventing an expanded use ofhuman bone marrow transplantation (1, 2). Although it is theoretically possible to avoid GVHD by careful histocompatibility matching, it is not currently feasible to match donor and recipient routinely for all major histocompatibility antigens. Moreover, there are no in vitro tests to detect minor antigenic disparities that can also stimulate 1. Abbreviations used in this paper: CTL, cytotoxic T lymphocytes; GVHD, graft vs. host disease; Leu-Leu-OMe, L-leucyl-L-leucine methyl ester, MST, mean survival time; NK, natural killer cells.
GVHD (3) . Because numerous studies in laboratory animals have shown that removal of immunocompetent T lymphocytes from the donor inoculum will prevent GVHD (4, 5) , the approaches to obviate GVHD in man have also focused on deleting T cells from the donor marrow. The available methodology for human T cell depletion, however, has not proven uniformly effective in preventing GVHD (6) (7) (8) (9) .
In this study we explored a new approach to the prevention of GVHD. Using a murine model of bone marrow transplantation, we examined the effects of treating the donor inoculum with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe), a compound that eliminates cells with cytotoxic potential (10) . LeuLeu-OMe has been shown to be toxic to human natural killer cells (NK), activated cytotoxic T cells (CTL), precursors of CTL (pre-CTL), and monocytes (1 1). Of importance, both CD8-positive and CD4-positive precursors and effectors of CTL are removed from mixed cell populations by Leu-Leu-OMe. By contrast, helper T cells, B cells, and a variety of nonhemopoietic cells are unaffected (10, 11) . In recent experiments murine NK and pre-CTL were found to be very similar to human cells in concentration-dependent sensitivity to Leu-Leu-OMe (12) . To determine whether Leu-Leu-OMe might affect the induction of, or alter the pattern oftissue injury in GVHD, we used a murine model of bone marrow transplantation that is skewed toward GVHD in that it crosses major histocompatibility barriers and uses a severalfold excess of donor T cells. The experimental results indicate that Leu-Leu-OMe treatment of the donor inoculum had the capacity to prevent lethal GVHD with no apparent toxic effects on stem cell function.
Methods
Mice. Female, 8-16-wk-old, C57BL/6J (B6) and (C57BL/6J X DBA/ 2J)F1 mice (B6D2FI) were used as donors and recipients, respectively. Treatment of donor cells and transplantation. Spleen and marrow cells were obtained as previously described (13) , and mixed at varying ratios. The mixtures were then washed once and resuspended at a concentration of 2.5 X 106 cells/ml either in phosphate-buffered saline (PBS) or in Leu-Leu-OMe dissolved in PBS. Leu-Leu-OMe wtss synthesized from leucyl-leucine as previously described (10) . After a 15-min incubation at room temperature, the cells were washed once, suspended in Hanks' balanced salt solution, counted, and infused via a lateral tail vein into irradiated (950 cGy) Fl recipients.
As previously described, immediately after treatment with Leu-LeuOMe, there was less than a 5% loss of viable donor cells. Following a 3-h incubation at 37°C, however, the number of Lyt-2+ spleen cells was decreased by more than 65%, whereas there was no alteration in the number of L3T4' cells (12) .
Survival studies. Survival times were measured from the day of transplantation to the day ofdeath. Deaths occurring within 8 Leu-Leu-OMe as above and then infused into 950 cGy irradiated syngeneic recipients. 5 d later, splenic 5-iodo-2-deoxyuridine-1251 ('25I-UdR) uptake was measured as previously described (15) .
Histology. Organs of recipient mice were fixed in 10% buffered formalin. Sections were stained with Hematoxylin and Eosin.
Results
Survival oftransplanted mice. To assess the effects of Leu-LeuOMe treatment of the donor inoculum on lethal GVHD, we incubated B6 donor cells with varying concentrations of LeuLeu-OMe before infusing them into irradiated B6D2F1 recipients. As shown in Fig. 1 Table   I indicate that treatment with 250 AM Leu-Leu-OMe had no deleterious effect on this measure of stem cell function. Since human marrow obtained for use in transplantation has variable amounts ofperipheral blood contamination, we also studied the stem cell function of a mixture of murine spleen and marrow incubated with Leu-Leu-OMe. Again there was no decrement in '25I-UdR uptake, suggesting that "bystander" stem cells are not damaged when the numerous cytotoxic cells are lysed by Leu-Leu-OMe. Histologic examination of spleens 5 d after irradiation revealed the expected hypocellularity in the nontransplanted control group and equivalent erythrocytic, granulocytic, and megakaryocytic regeneration in the spleens of recipients of treated or nontreated marrow cells (Fig. 3) .
Discussion
This study indicates that Leu-Leu-OMe treatment ofdonor cells is able to prevent lethal GVHD across major histocompatibility (11) ; murine lymphocytes are similarly affected (12) . Indeed, the concentration-dependent capacity of Leu-Leu-OMe to eliminate murine splenic cytotoxic T cells closely parallels its efficacy in reducing the severity of GVHD. The incubation of B6 spleen cells with 100 MM LeuLeu-OMe results in complete loss ofNK function but only partial reduction of the generation ofallospecific cytotoxic T cells (12) . As anticipated from the results above, incubation of B6 spleen and marrow cells with 125 MuM Leu-Leu-OMe delayed, but did not eliminate death from GVHD (Fig. 1 A) . Treatment of cells with 250 MM Leu-Leu-OMe caused near total ablation of allocytotoxicity (12) and prevented lethal GVHD (Fig. 1, A MM Leu-Leu-OMe (<5%) (12) were insufficient in the 25 X 106 inoculum to cause any GVHD, but were sufficient in the 50 X 106 inoculum to cause the self-limited cutaneous GVHD and the mild chronic hepatic GVHD. However, the possibility remains that a Leu-Leu-OMe-resistant, noncytotoxic cell of low frequency in the donor inoculum caused the limited GVHD seen in the recipients of 50 X 106 B6 cells and the more severe GVHD seen in the recipients ofimmune B6 cells. Studies using other models of murine GVHD have suggested a role for helper T cells in causing a periportal lymphocytic infiltrate in the liver (21) and dermal sclerosis (22) . These hypotheses are not mutually exclusive. It should be noted, however, that in the current studies even these nonlethal manifestations of GVHD were only observed when very large numbers ofdonor Leu-Leu-OMe treated donor cells were used.
The present studies clearly demonstrate the selective nature of the effects of Leu-Leu-OMe. Leu-Leu-OMe had no discernible toxicity for marrow stem cells, yet prevented GVHD. Erythroid regeneration, as assessed by splenic '25I-UdR uptake, was not diminished (Table I) and newly generated granulocytic, erythrocytic and megakaryocytic elements were observed histologically following treatment with Leu-Leu-OMe (Fig. 3) . In contrast to current regimens used in human bone marrow transplantation, Leu-Leu-OMe treatment of donor marrow is a relatively rapid and simple technique. Because Leu-Leu-OMe appears to delete certain cells based on their functional capabilities, rather than on their cell surface markers, it may offer a new approach to avoid GVHD in humans.
